Dishman Carbogen Amcis is currently trading at RS. 212.50, rising by 1.75 points or 0.83% from its previous close of RS. 210.75 on the BSE.

The stock opened at RS. 215.10 and recorded a high of RS. 217.20 and a low of RS. 212.00 during the session. So far, 18,070 shares have been traded on the exchange.

This BSE group 'A' stock, with a face value of RS. 2, touched a 52-week high of RS. 307.80 on December 11, 2024, and a 52-week low of RS. 132.75 on June 4, 2024. Over the past week, the stock has traded between a high of RS. 217.20 and a low of RS. 206.10. The company's current market capitalization stands at RS. 3340.26 crore.

Promoter holding in the company is at 59.32%, while institutional investors and non-institutional investors hold 10.74% and 29.94% respectively.

In a major development, the company’s wholly owned subsidiary, Carbogen Amcis, has received its first Drug Manufacturing License (DML) from China’s National Medical Products Administration (NMPA) for its Shanghai facility. This approval followed a thorough review process focused on Good Manufacturing Practice (GMP) compliance and operational readiness.

Located in the Shanghai Chemical Industry Park (SCIP), the 40,000m² site is a self-sufficient facility designed for early-phase research, pilot-scale production, and commercial GMP manufacturing. It provides end-to-end services from raw materials to active pharmaceutical ingredients (APIs), including high potency material handling and micronization. With four segregated units and reactor capacities ranging from 50 to 6,300 litres, the facility is built for flexibility and scalability, employing over 140 professionals from around the globe.

Dishman Carbogen Amcis (DCAL), established in 1983, began as a manufacturer of quaternary ammonium and phosphate compounds. Today, it has evolved into a fully integrated CRAMS (Contract Research and Manufacturing Services) company working with global pharmaceutical innovators.